"I am deeply honored to be named to the TIME100 Health list," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals. "Every disruptor dreams of the moment that culture reflects that what ...
Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.
(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...
In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was published with a major revision to the sexual dysfunction categories, and the diagnosis of female ...
Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...
Hosted on MSN
Addyi: FDA approves libido-boosting drug for postmenopausal women – what does it mean for women’s sexual health?
U.S. health authorities have widened the approval of a closely debated medication designed to increase female libido, allowing the once-daily pill to be used by women over the age of 65. The decision, ...
Please provide your email address to receive an email when new articles are posted on . Many midlife women experience hypoactive sexual desire disorder, which can impact both relationships and mental ...
On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in women who are past menopause. Addyi works by addressing neurotransmitters like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results